Paracelsian AndroVir "supports normal immune function" in HIV patients -- preliminary data.
This article was originally published in The Tan Sheet
Executive Summary
PARACELSIAN ANDROVIR "SUPPORTS NORMAL IMMUNE FUNCTION" IN HIV PATIENTS, according to preliminary results of a nine-week Phase I trial of 16 patients released by the Ithaca, N.Y.-based company. "The design of this trial was to introduce increasingly larger amounts of AndroVir in relatively short periods of time," Paracelsian said. "The effect on HIV-1 viral load and CD4 cells demonstrated in this clinical study indicates that AndroVir supports normal immune function."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning